73 related articles for article (PubMed ID: 15345308)
1. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.
Jones SA; Scheller J; Rose-John S
J Clin Invest; 2011 Sep; 121(9):3375-83. PubMed ID: 21881215
[TBL] [Abstract][Full Text] [Related]
2. Cloning of novel soluble gp130 and detection of its neutralizing autoantibodies in rheumatoid arthritis.
Tanaka M; Kishimura M; Ozaki S; Osakada F; Hashimoto H; Okubo M; Murakami M; Nakao K
J Clin Invest; 2000 Jul; 106(1):137-44. PubMed ID: 10880057
[TBL] [Abstract][Full Text] [Related]
3. A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease.
Mitsuyama K; Tomiyasu N; Suzuki A; Takaki K; Takedatsu H; Masuda J; Yamasaki H; Matsumoto S; Tsuruta O; Toyonaga A; Sata M
Clin Exp Immunol; 2006 Jan; 143(1):125-31. PubMed ID: 16367943
[TBL] [Abstract][Full Text] [Related]
4. Structure of the extracellular domains of the human interleukin-6 receptor alpha -chain.
Varghese JN; Moritz RL; Lou MZ; Van Donkelaar A; Ji H; Ivancic N; Branson KM; Hall NE; Simpson RJ
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):15959-64. PubMed ID: 12461182
[TBL] [Abstract][Full Text] [Related]
5. The Role of IL-6RA in UHMWPE Promotes Proliferation in Fibro-Like Synovial Cells.
Pang X; Yang J; Zhen X; Nie H; Qin H; Huang L; Zhang L
Biomed Res Int; 2018; 2018():3928915. PubMed ID: 30426007
[TBL] [Abstract][Full Text] [Related]
6. Cellular and Oxidative Mechanisms Associated with Interleukin-6 Signaling in the Vasculature.
Didion SP
Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186034
[TBL] [Abstract][Full Text] [Related]
7. Response of plasma IL-6 and its soluble receptors during submaximal exercise to fatigue in sedentary middle-aged men.
Gray SR; Robinson M; Nimmo MA
Cell Stress Chaperones; 2008; 13(2):247-51. PubMed ID: 18320358
[TBL] [Abstract][Full Text] [Related]
8. Abrogation of viral interleukin-6 (vIL-6)-induced signaling by intracellular retention and neutralization of vIL-6 with an anti-vIL-6 single-chain antibody selected by phage display.
Kovaleva M; Bussmeyer I; Rabe B; Grötzinger J; Sudarman E; Eichler J; Conrad U; Rose-John S; Scheller J
J Virol; 2006 Sep; 80(17):8510-20. PubMed ID: 16912301
[TBL] [Abstract][Full Text] [Related]
9. IL-6 transsignaling: the in vivo consequences.
Jones SA; Richards PJ; Scheller J; Rose-John S
J Interferon Cytokine Res; 2005 May; 25(5):241-53. PubMed ID: 15871661
[TBL] [Abstract][Full Text] [Related]
10. The soluble IL-6 receptors: serum levels and biological function.
Montero-Julian FA
Cell Mol Biol (Noisy-le-grand); 2001 Jun; 47(4):583-97. PubMed ID: 11502067
[TBL] [Abstract][Full Text] [Related]
11. Development of a monoclonal antibody-based enzyme-linked immunoabsorbent assay for the binding of gp130 to the IL-6/IL-6R complex and its competitive inhibition.
Scheller J; Kovaleva M; Rabe B; Eichler J; Kallen KJ; Rose-John S
J Immunol Methods; 2004 Aug; 291(1-2):93-100. PubMed ID: 15345308
[TBL] [Abstract][Full Text] [Related]
12. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses.
Müller-Newen G; Küster A; Hemmann U; Keul R; Horsten U; Martens A; Graeve L; Wijdenes J; Heinrich PC
J Immunol; 1998 Dec; 161(11):6347-55. PubMed ID: 9834125
[TBL] [Abstract][Full Text] [Related]
13. The N-terminus of gp130 is critical for the formation of the high-affinity interleukin-6 receptor complex.
Moritz RL; Ward LD; Tu GF; Fabri LJ; Ji H; Yasukawa K; Simpson RJ
Growth Factors; 1999; 16(4):265-78. PubMed ID: 10427501
[TBL] [Abstract][Full Text] [Related]
14. Specific inhibition of IL-6 signalling with monoclonal antibodies against the gp130 receptor.
Liautard J; Sun RX; Cotte N; Gaillard JP; Mani JC; Klein B; Brochier J
Cytokine; 1997 Apr; 9(4):233-41. PubMed ID: 9112331
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis.
Mees ST; Toellner S; Marx K; Faendrich F; Kallen KJ; Schroeder J; Haier J; Kahlke V
J Surg Res; 2009 Dec; 157(2):235-42. PubMed ID: 19589542
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
